Streamlining The Biological Factory: Making A Better CHO Cell For Biopharma Production

SAFC's CHOZN® Platform has been developed as a ‘plug and play' manufacturing system for the creation of biopharmaceutical producing cell lines. The design criteria were initially focused on the production of therapeutic monoclonal antibodies, but it can also be used for other recombinant biologics, such as different types of proteins and vaccines. From the introduction of DNA into the CHO (Chinese hamster ovary) cell, all the way through to the process development stages, SAFC has developed a system that includes not only the cell line, but all the media, feed media and optimized procedures required for the fast selection of high producing cell lines for a therapeutic monoclonal antibody. In this white paper, SAFC discusses the development of this cell platform and how it affects the market.

During development of the CHOZN Platform, there was a focus on creating cells that gave high production titers and improved growth characteristics to produce high-quality proteins. The system can be used to express any antibody using the same parental cell line and the same media and feed formulations. All that is changed is the DNA that is introduced into the CHO cell, which creates the desired product in the cell culture.